about
Novel histone deacetylase inhibitors in clinical trials as anti-cancer agentsEssential roles of four-carbon backbone chemicals in the control of metabolismApicidin F: characterization and genetic manipulation of a new secondary metabolite gene cluster in the rice pathogen Fusarium fujikuroiEpigenetic modulation with HDAC inhibitor CG200745 induces anti-proliferation in non-small cell lung cancer cellsHistones: Controlling Tumor Signaling CircuitryEpigenetic regulation of protein tyrosine phosphatases: potential molecular targets for cancer therapy.The Histone Deacetylase Inhibitor Trichostatin A Sensitizes Human Renal Carcinoma Cells to TRAIL-Induced Apoptosis through Down-Regulation of c-FLIPL.Combination phenylbutyrate/gemcitabine therapy effectively inhibits in vitro and in vivo growth of NSCLC by intrinsic apoptotic pathwaysBeyond Field Effect: Analysis of Shrunken Centroids in Normal Esophageal Epithelia Detects Concomitant Esophageal Adenocarcinoma.Emerging drugs for hepatocellular carcinoma.Current evidence for histone deacetylase inhibitors in pancreatic cancer.Histone deacetylase inhibitors and pancreatic cancer: are there any promising clinical trials?Epigenetic regulation of ZEB1-RAB25/ESRP1 axis plays a critical role in phenylbutyrate treatment-resistant breast cancer.Cardiomyogenic Differentiation of Human Dental Follicle-derived Stem Cells by Suberoylanilide Hydroxamic Acid and Their In Vivo Homing PropertyPreclinical Pharmacokinetics Study of R- and S-Enantiomers of the Histone Deacetylase Inhibitor, AR-42 (NSC 731438), in RodentsThe role of HDACs inhibitors in childhood and adolescence acute leukemias.Epigenetic regulation in myelodysplastic syndromes: implications for therapy.Microbial communication leading to the activation of silent fungal secondary metabolite gene clusters.HDAC2 overexpression is a poor prognostic factor of breast cancer patients with increased multidrug resistance-associated protein expression who received anthracyclines therapy.Histone deacetylase inhibitor MS-275 alone or combined with bortezomib or sorafenib exhibits strong antiproliferative action in human cholangiocarcinoma cells.SelSA, selenium analogs of SAHA as potent histone deacetylase inhibitors.Suppression of adipogenesis by valproic acid through repression of USF1-activated fatty acid synthesis in adipocytes.Comparative mutagenicity of apicidin and apicidin derivatives (SD-0203 and SD-2007), histone deacetylase inhibitors.
P2860
Q21198868-750646B2-342D-4188-96A9-52345C9C126EQ26795753-CD6583C1-D6CC-4043-87CE-679E0504F9B2Q28541163-63F3A288-1969-4536-9F4C-3672E6C77B45Q28544442-2ED315D8-A3D7-4A52-9B5C-F25001135671Q34109472-1EC280B8-1389-419B-ACC0-6086F47D2393Q34528296-C83DFCB9-8ABB-481F-82AA-7DF85E5DB379Q34865077-FCCA1182-A8D0-4006-BDA9-81D62B509B4EQ35173372-28166E83-060D-4EAD-9436-5DB6B10BF916Q36570795-7456BD6F-1F55-46B0-9FDF-7F358E8CF618Q36580595-E85CC9F3-2970-4BFD-A621-EA42964BD412Q36616790-217C08FC-F1C2-4241-BC88-9883BBCAB98BQ36654454-A4AEEAC5-2331-4D6E-B0CE-25C7F0AA2E28Q36738957-16B866C4-5F04-4DBA-B14C-32409AFC1EB3Q37428137-05580DAB-D0AC-44C8-9A74-AA3ED9EA1B9CQ37600352-7A720974-A659-4C23-92E5-01ACF16C9F38Q37841146-332376B8-E683-401B-82F6-550AD801C7C0Q37850456-910A30B5-43C5-4EFE-A424-EA84050DDE69Q38459251-D8E45883-6D10-4D79-A844-C754C6BF0B1EQ39586909-AA96A66D-F378-4D6F-9D1F-AE1115B3DC7CQ40088575-7AF4E7CA-61A5-4D97-BF3A-DB7D82D2F292Q41487113-9824F924-A1B2-4740-9C79-920638D17418Q42806968-DD7AC4C0-2794-4509-B12E-322AE9F9FAC0Q50085341-EF012D51-7E63-4549-8B87-DD251DDBAB00
P2860
description
2002 nî lūn-bûn
@nan
2002 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Histone deacetylase inhibitors and anticancer therapy.
@ast
Histone deacetylase inhibitors and anticancer therapy.
@en
type
label
Histone deacetylase inhibitors and anticancer therapy.
@ast
Histone deacetylase inhibitors and anticancer therapy.
@en
prefLabel
Histone deacetylase inhibitors and anticancer therapy.
@ast
Histone deacetylase inhibitors and anticancer therapy.
@en
P356
P1476
Histone deacetylase inhibitors and anticancer therapy.
@en
P2093
Kouraklis G
Theocharis S
P304
P356
10.2174/1568011023353921
P577
2002-07-01T00:00:00Z